{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Saleh KM"],"pubmed_abstract":["<h4>Background</h4>Pulmonary arterial hypertension (PAH) is a progressive, fatal cardiopulmonary disorder characterized by elevated pulmonary vascular resistance leading to right heart failure. Current treatment utilizes pathway-specific vasodilators, including numerous prostacyclin therapies with diverse delivery methods. Despite available options, head-to-head studies comparing these treatments remain scarce.<h4>Aim</h4>This network meta-analysis seeks to systematically evaluate all prostacyclin-based PAH therapies to guide clinical decision-making regarding treatment selection.<h4>Methods</h4>We implemented a frequentist approach to network meta-analysis (NWM). For continuous outcomes, we calculated pooled mean differences (MD), whereas risk ratios (RR) were determined for binary endpoi"],"journal":["Frontiers in medicine"],"pagination":["1643220"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12554579"],"repository":["biostudies-literature"],"pubmed_title":["Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis."],"pmcid":["PMC12554579"],"pubmed_authors":["Alazazzi H","Bodi G","Mallat J","Mohammed S","Iqbal T","Sabbour H","Elhennawi M","Saleh KM","Salim S"],"additional_accession":[]},"is_claimable":false,"name":"Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis.","description":"<h4>Background</h4>Pulmonary arterial hypertension (PAH) is a progressive, fatal cardiopulmonary disorder characterized by elevated pulmonary vascular resistance leading to right heart failure. Current treatment utilizes pathway-specific vasodilators, including numerous prostacyclin therapies with diverse delivery methods. Despite available options, head-to-head studies comparing these treatments remain scarce.<h4>Aim</h4>This network meta-analysis seeks to systematically evaluate all prostacyclin-based PAH therapies to guide clinical decision-making regarding treatment selection.<h4>Methods</h4>We implemented a frequentist approach to network meta-analysis (NWM). For continuous outcomes, we calculated pooled mean differences (MD), whereas risk ratios (RR) were determined for binary endpoi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-05T07:53:20.688Z","creation":"2026-05-14T03:12:55.233Z"},"accession":"S-EPMC12554579","cross_references":{"pubmed":["41158465"],"doi":["10.3389/fmed.2025.1643220"]}}